Aromatase inhibitors in breast cancer: A review of cost considerations and cost effectiveness

PharmacoEconomics

Volumn 24, Issue 3, 2006, Pages 215-232

  Karnon, Jonathan ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; MEGESTROL; PLACEBO; TAMOXIFEN;

ADVANCED CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; EARLY CANCER; ECONOMIC EVALUATION; ENDOMETRIUM CANCER; FRACTURE; HEALTH CARE; HEART INFARCTION; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

AROMATASE INHIBITORS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS;

EID: 33644871944     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624030-00002     Document Type: Review

References (45)

1. Ferlay J, Bray F, Pisani P, et al. Globocan/Eucan 2000: cancer incidence, mortality and prevalence worldwide [online]. Available from URL: http://www-dep.iarc.fr/datava/infodata.htm [Accessed 2004 Feb 16]
2. Will BP, Berthelot J-M, Le Petit C, et al. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000; 36: 724-35
3. Stockler M, Wilcken NRC, Ghersi D, et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000; 26: 151-68
4. Haller DG, Fox KR, Schucter LM. Metastatic breast cancer. In: Fowble B, Goodman RL, Glick JH, et al., editors. Breast cancer treatment: a comprehensive guide to management. St Louis (MO): Mosby Year Book, 1991
5. National Cancer Institute. Aromatase inhibitors [online]. Available from URL: http://www.cancer.gov/clinicaltrials/developments/aromatase-inhibitors- digest/allpages [Accessed 2006 Jan 30]
6. Tamaki Y, Miyoshi Y, Kim SJ, et al. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer. Expert Rev Anticancer Ther 2003; 3: 193-201
7. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new aromatase inhibitor for advanced breast cancer: double blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-61
8. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethamide in postmenopausal women with advanced breast cancer. Ann Oncol 1998; 9: 639-45
9. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19: 3357-66
10. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and slective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma. Cancer 1997; 79: 730-9
11. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megesterol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000; 18: 1399-411
12. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group [published erratum appears in J Clin Oncol 2001; 19: 3302].
13. J Clin Oncol 2001; 19: 2596-606
14. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-67
15. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-57
16. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 2003; 349 (19): 1793-802
17. Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). 2005 ASCO Annual Meeting; 2005 May 13-17; Orlando [online]. Available from URL: http://www.asco.org/ac/1,1003,_12-002643-00_18-0034-00_19- 0031396,00.asp [Accessed 2006 Jan 30]
18. Thurlimann B. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer: BIG 1-98. A prospective randomized double-blind phase III study. Proceedings of the St Gallen Primary Therapy of Early Breast Cancer 2005 [online]. Available from URL: http://www.ibcsg.org/public/documents/pdf/divers/BIG_1-98_StGallen_2005.pdf [Accessed 2005 Jun]
19. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-2
20. Jakesz R, Kaufmann M, Gnant M, et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial [abstract]. Proceedings of the San Antonio 2003 Breast Cancer Symposium. Breast Cancer Res Treat 2004; 88 Suppl. 1: S7 (2)
21. Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment [abstract]. Proceedings of the San Antonio 2002 Breast Cancer Symposium. Breast Cancer Res Treat 2003; 82 Suppl. 1: S6 (3)
22. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-92
23. Baum M. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control 2004; 11 (4): 217-21
24. Breast Cancer Disease Site Group. The role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer, Practice Guideline Report #1-5, 2003 [online]. Available from URL: http://www.cancercare. on.ca/pdf/pebc1-5s.pdf [Accessed 2006 Jan 30]
25. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA-17 randomized placebo controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer [abstract]. Proc Am Soc Clin Oncol 2004; 88s: 847
26. Karnon J, Jones T. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy for advanced breast cancer in postmenopausal patients. Pharmacoeconomics 2003; 21 (7): 513-25
27. Karnon J, Johnston SRD, Jones T, et al. A trial-based economic evaluation of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal, advanced breast cancer. Ann Oncol 2003; 14: 1629-33
28. Delea T, Smith R, Karnon J. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy for postmenopausal women with advanced breast cancer: the US perspective. Breast Cancer Res Treat 2002; 76 (Suppl. 1): S136 and poster
29. Dranitsaris G, Verma S, Trudeau M. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am J Clin Oncol 2003; 26: 289-96
30. Nuijten M, Meester L, Waibel F, et al. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics 1999; 16: 379-97
31. Nuijten M, Fitzimon C, Waild F. Economic evaluation of le-trozole in the treatment of advanced breast cancer in postmenopausal women in Canada. Value Health 2000; 3 (1): 31-9
32. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost utility assessments in oncology. J Clin Oncol 2000; 18: 3302-17
33. Karnon J, Johnston SRD, Delea TE, et al. Cost-effectiveness of extended adjuvant letrozole after five years of tamoxifen in postmenopausal early breast cancer [abstract 6044]. J Clin Oncol 2004; 22 (July 15 Suppl.): 6044. ASCO Annual Meeting Proceedings (post-meeting edition) [online]. Available from URL: http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-003243,00.asp [Accessed 2006 Jan 18]
34. Delea TE, Karnon J, Smith RE, et al. Cost-effectiveness of five years of extended adjuvant letrozole in postmenopausal women with early breast cancer who have completed five years of adjuvant tamoxifen. San Antonio Breast Cancer Symposium, 2004 [online]. Available from URL: http://www.abstracts2view.com/ sabcs/view.php?.nu=BCS4L_876 [Accessed 2005 Jul 31]
35. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004; 101 (6): 1311-22
36. Locker GY, on behalf of the ATAC Trialists' Group. Cost-utility analysis of anastrozole versus tamoxifen as primary adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare system perspective: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8-11; San Antonio
37. Mansel R. Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: a UK national health service perspective. 29th ESMO Congress; 2004 Oct 29-Nov 2; Vienna, Austria
38. Brown R, Benedict A, Mansel R. Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: a UK national health service perspective. ISPOR 7th Annual European Congress; 2004 Oct 24-26; Hamburg, Germany
39. Verma S, Rocchi A, Cheung S. Canadian cost-effectiveness analysis of anastrozole versus tamoxifen in early breast cancer. 26th San Antonio Breast Cancer Symposium; 2003 Dec 3-6; San Antonio (TX)
40. Karnon J, Delea T, Johnston SRD, et al. Cost-effectiveness of letrozole versus tamoxifen as early adjuvant therapy in postmenopausal women with early breast cancer. 7th Milan Breast Cancer Conference; 2005 Jun 15-17; Milan, Italy
41. Karnon J, Delea TE, Barghout V, et al. Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer in the UK [poster]. ISPOR 8th Annual European Congress; 2005 Nov 6-8; Florence
42. Delea TE, Karnon J, Thomas SK, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective [poster]. 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio
43. Annemans L, Moeremans K, Lamarque H. Health economic assessment of the ATAC trial comparing anastrozole versus tamoxifen in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer [abstract]. ISPOR 7th Annual European Congress; 2004 Oct 24-26; Hamburg
44. Sorensen S, Brown R, Benedict A, et al. Patient-rated utilities in postmenopausal early breast cancer: a cross country comparison. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 7th Annual European Congress; 2004 Oct 24-26; Hamburg
45. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998 May 16; 351 (9114): 1451-67